SANTEN PHARMACEUTICAL CO.,LTD. (4536.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	291.6B	291.6B	300.0B	302.0B	279.0B
Cost of Revenue	—	121.9B	129.0B	123.3B	113.0B
Gross Profit	—	169.7B	171.0B	178.7B	166.1B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	—	89.6B	88.0B	91.5B	96.3B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	4.4B	3.9B	15.3B	38.6B
Total Operating Expenses	—	94.0B	91.8B	106.8B	134.9B
Cost and Expenses	243.8B	243.8B	253.1B	263.4B	282.1B
Operating Income (EBIT)	47.8B	47.8B	46.9B	38.5B	(3.1B)
Non-Operating
Interest Income	—	1.6B	4.0B	1.6B	1.2B
Interest Expense	—	2.0B	2.7B	2.7B	1.5B
Net Interest Income	—	(355.0M)	1.3B	(1.1B)	(346.0M)
Other Non-Op Income/Expense	—	7.0B	589.0M	1.5B	3.5B
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	—	47.4B	47.5B	29.9B	(5.8B)
Income Tax Expense	—	9.9B	11.6B	3.2B	9.2B
Bottom Line
Net Income	37.4B	37.4B	36.3B	26.6B	(14.9B)
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	37.6B	37.6B	35.9B	26.7B	(15.0B)
Per Share
Basic EPS	¥113	¥114	¥104	¥73	(¥39)
Diluted EPS	¥113	¥114	¥104	¥72	(¥39)
Revenue Per Share	¥890	¥890	¥861	¥823	¥720
Shares
Basic Shares Outstanding	327.6M	327.6M	348.6M	366.9M	387.4M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	31.7B	66.2B	64.8B	56.7B	14.2B
D&A	13.8B	18.4B	17.9B	18.2B	17.2B
EBIT	47.8B	47.8B	46.9B	38.5B	(3.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026